This trial is testing a new chemotherapy drug to see what the best dose is and what side effects it causes. The drug works by killing cancer cells or stopping them from growing.
4 Primary · 5 Secondary · Reporting Duration: Up to 1.5 years
38 Total Participants · 1 Treatment Group
Primary Treatment: Liposome-encapsulated Daunorubicin-Cytarabine · No Placebo Group · Phase 1
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: